| Monday June 23 |
| 08:45-09:00 |
Welcome and Introduction |
| 09:00-10:20 |
Oral session I |
Free communications |
chair: Leon Aarons |
| |
Per Olsson |
A population PK/PD model for the irreversible inhibition of 5alpha- reductase types 1 and 2, and the effects on plasma dihydrotestosterone levels |
| |
Rik de Greef |
The use of compliance data in the analysis of a clinical trial of antiretroviral drugs in HIV+ individuals |
| |
Namik Taright |
Non-stationarity of kinetic parameters in multi-occasion designs |
| |
J. Wang |
Two-stage procedures for the analysis of cross-over trials using pharmacokinetic and pharmacodynamic models |
| |
Christine Veyrat-Follet |
Is ipecac model a good predictor of concentration-efficacy response to ondansetron in patients? |
| 10:20-10:50 |
Coffee |
| 10:50-12:40 |
Oral session II |
Categorical variables |
chair: Ferdie Rombout |
| |
Stuart Beal |
Analyzing odd type data using NONMEM |
| |
Adrian Dunne |
Population analysis of ordinal categorical data. |
| |
Jon Wakefield |
The Bayesian approach to categorical responses |
| 12:40-14:00 |
Lunch |
| 14:00-15:30 |
Oral session III |
Clinical applications |
chair: Duncan Jodrell |
| |
Etienne Chatelut |
Subsequent developments of formulas designed for predicting carboplatin clearance in adults and in children |
| |
Alan Boddy |
Population pharmacokinetics of etoposide in children |
| |
Jean-Louis Steimer |
Mixed-effects modelling of the dose-AUC relationship of saquinavir single dose in healthy subjects |
| |
David Lunn |
The pharmacokinetics of saquinavir: a Markov chain Monte-Carlo population analysis |
| 15:30-16:00 |
Coffee/Tea |
| 16:00-17:30 |
Oral session IV |
New Developments and Softwares |
chair: France Mentré |
| |
Anthony Hunt |
A paradigm for validating methodologies to simulate clinical trials validation of pharmacodynamic predictions |
| |
Nicky Best |
New developments in the BUGS software for Bayesian modelling |
| |
Roberto Gomeni |
NPML-FIT: a graphical nonparametric population modelling program |
| |
Niclas Jonsson |
XPOSE 2.0 - an SPLUS based population model building aid for NONMEM |
| |
| |
| Tuesday 24 June |
| 09:00-10:00 |
Oral session V |
Discussion Topics I |
chair: Janet Wade |
| |
Don Nicholls |
Experiences with genotype and phenotype information in mixed effects modelling |
| |
Niclas Jonsson |
Covariate model building in population analysis |
| |
Lutz Harnisch |
The estimation of drug-drug interactions in population pharmacokinetic trials |
| 10:00-12:00 |
Poster and software session |
| 12:00-13:15 |
Oral session VI |
Discussion Topics II |
chair: Janet Wade |
| |
Karin Fattinger |
The estimation of drug input rate functions by nonparametric subject- specific population deconvolution |
| |
Pascal Girard |
Undercompliance and population pharmacokinetics. |
| |
Mats Karlsson |
Assumption testing in population pharmacokinetic models |
| 13:15 |
Closure followed by light lunch |
Poster Presentations
Aarons L, Gupta, SK A mixed-effects modelling approach to the analysis of verapamil-GITS blood pressure data
Bleyzac N., Vial F., Allard-Latour B., Mouret J. , Jelliffe RW , Maire PH Contribution of nonparametric population pharmacokinetic software to the determination of diurnal variations of drug pharmacokinetic parameters
Dubruc C, Mesnil F, Thenot JP, Mentré F. Population pharmacokinetic analysis of mizolastine in healthy young volunteers and allergic patients using NONMEM
Ebelin M-E, Mentré F, Burtin P, Laplanche R Pharmacokinetic population analysis of SDZ ENA 713 and its metabolite in patients; relationships with efficacy, safety and tolerability
Frey, N., Laveille C., Kiefer Ph., Laudignon N, Jochemsen R. Population pharmacokinetics/pharmacodynamics of a new formulation of gliclazide in 224 type 2 diabetics.
Garcia MJ, Santos Buelga D, Otero Mj, Serrano J, Blanco B, Dominguez-Gil A. Population pharmacokinetics: effect of polytherapy on valproic acid clearance
Jonsson N and Karlsson M Covariate model building in population analysis using a bootstrap resampling procedure
Khan, AZ, Pitsiu, M., Aarons, LA, Parivar, K, Widman, M Population pharmacokinetic analysis of eltanolone
Larsson P, Weibull E, Pedersen S Estimation of bioavailability using a semi-simultaneous design
Laveille C., Frey N, Lerebours G, Resplandy G, Jochemsen R. Population pharmacokinetics-pharmacodynamics of a new specific bradycardic agent (S16257) and its metabolite (S 18982) evaluation of the drug/metabolite potency ratio
Modamio P, Jansat JM, Lastra CF, Marino EL Change in the analytical error function depending on the calibration curve range: implications for pharmacokinetic parameter estimation of carebastine.
Piotrovskij V., Van de Velde V., Van Pee A A population analysis of lubeluzole pharmacokinetics in healthy volunteers and patients with ischaemic stroke
du Preez M, Botha J, and McFadyen L A count model for analysing pk/pd data for theophylline in neonatal apnoea
Romano S, Falcao AC, Del Mar Fdz. De GattaM, Victoria Calvo M, Méndez E, Domínguez-Gil A, Lanao Pharmacokinetics of amikacin in intensive care unit patients: population analysis.
Rosario M, Sharp CA, Jodrell DI, Thomson AH Population pharmacokinetics of gentamicin in oncology patients
Rostami-Hodjegan A, Tucker GT On estimating half-life using population pharmacokinetics
Topping LP, Longford NT An alternative definition of individual bioequivalence
Tranchand B,Pobel C, Ardiet CJ, Parola JN, Ménard G Pharmacokinetic/dynamic modelling of neutropenic effect of melphalan using NONMEM associated with a cubic spline function
F. Trocóniz I, Naukkarinen T, Karlsson MO Population pharmacodynamic modelling of levodopa in Parkinsonian patients receiving the COMT inhibitor entacapone
